MCL1 and plasma cell myeloma: Indeed, flavopiridol blocks the growth of both multiple myeloma and chronic lymphocytic leukemia (CLL) cells, in which downregulation of Mcl-1, a Bcl-2 family member, was found to be flavopiridol’s primary mechanism of action.